Over the past 5--10 years there have been a number of events that have caused concern related to quality assurance in laboratories performing diagnostic testing in oncology and the accuracy of these tests, which ultimately determine patient therapy ([@R1]). Our field has recognized the danger in the lack of standardization of processes between different laboratories, the variability inherent in the analytical phase and the lack of control over the pre-analytical phase of tissue processing. Biospecimen science, the study of variables affecting biospecimen analysis, has identified a range of factors affecting the quality of harvested tissue ([@R2]--[@R5]). These factors, grouped as pre-analytical variables, represent a critical problem for biomarker measurement on tissue specimens that can lead to errors that affect patient care.

This issue is most prominent in breast cancer where it has been shown that pre-analytical variables, especially delayed time to formalin fixation (cold ischemic time), have affected companion diagnostic testing ([@R6]--[@R9]). Overall, it has been estimated that delay to formalin fixation and subsequent protein degradation within the tissue are responsible for a 10--20% false negative rate for ER in breast cancer ([@R1], [@R9]). A similar effect has been shown for HER2 with loss of protein and RNA as a function of increasing time to fixation of the tissue. These issues have prompted the American Society of Clinical Oncologists (ASCO) and the College of American Pathologists (CAP) to publish guidelines for the evaluation of ER, PgR and Her2 in breast cancer, limiting cold ischemic time to 60 minutes ([@R10], [@R11]).

The issue of pre-analytic variables is not limited to the companion diagnostics of breast cancer. Data have been published about the loss of antigenicity of phosphorylated proteins ([@R12]--[@R15]) and increased levels of hypoxia induced factors as well as markers of posttranslational modification as a consequence of delayed time to formalin fixation of harvested tissue ([@R16]). Also RNA degradation and time dependent modulation of gene expression have been observed as a cellular reaction to stress and sub-optimal pre-analytical processing conditions ([@R15]). Finally, the effects of pre-analytical variables on harvested tissue do not only play an important role for companion diagnostic testing and development of new drugs, but also in retrospective studies using archived tissue collections, where documentation of tissue handling and processing is often minimal.

Therefore it was our goal to develop and construct an intrinsic control for formalin fixed, paraffin embedded (FFPE) tissue that could be used in order to assess suitability of a given specimen of unknown quality for immunological assessments. Here we describe proof of concept for the development of a tissue quality index (TQI).

Material and Methods {#S1}
====================

Study Cohorts {#S2}
-------------

This prospectively designed study included 3 different cohorts of breast tissue, all of which have exact information on pre-analytical specimen handling and processing with focus on cold ischemic time. All tissue was used after approval from the Rochester Institutional Review Board, from the Yale Human Investigation Committee protocol \#8219 or \#25173, or from the ethic institutional review board for "Biobanking and use of human tissue for experimental studies" of the Pathology Services of the Azienda Ospedaliera Città della Salute e della Scienza di Torino. Written informed consent was obtained from all patients for their tissue to be used in research.

### Time to Fixation Breast Cancer Series (TFBC) {#S3}

Formalin-fixed, paraffin-embedded (FFPE) tissues of 93 breast cancer patients, who underwent surgery at the University of Rochester, School of Medicine, (Rochester, NY), were collected. Time from surgical resection to immersion of the specimen in formalin was recorded and ranged from 25 to 415 minutes. A tissue microarray (TMA) was constructed, consisting of these 93 breast cancer specimens, cell lines and controls, all represented in two fold redundancy (two histospots per patient specimen).

### Normal Breast Tissue Series (NBT) {#S4}

Normal breast tissues from 11 breast reduction mammoplasties were collected. Tissue from each patient was divided into different parts and exposed to pre-defined and controlled pre-analytical variables, with time points until immersion of the tissue into formalin at 20 minutes, 2 hours, 24 hours and 48 hours after surgical removal of the tissue. A TMA was constructed representing these specimens with variable conditions in 4 fold redundancy.

### Italian Breast Cancer Series (IBC) {#S5}

Tissues from 100 breast cancer cases were collected and time until formalin fixation of these tissues was recorded, ranging from 1 to 72 hours. This cohort differs from the time to fixation breast cancer series in a way that tissues were vacuum sealed and stored at 4 degree Celsius (UVSC) right after surgical removal until gross dissection and immersion of the tissue into formalin ([@R17]). TMAs were constructed consisting of the 100 breast cancer specimens represented in two fold redundancy.

Cell Lines and Cell Culture {#S6}
---------------------------

The cell lines T47D, BT474, SKBR3, MB231, MB468, CHO, A431, HT29, A59--195, and A82-68-B were purchased from ATCC (Manassas, VA), cultured in our lab, and used to create control cell line cell blocks for TMA standardization. Culture conditions and construction of cell pellets for TMAs have been described previously ([@R18]).

TMA Construction {#S7}
----------------

The TMAs for the 3 breast tissue series were constructed as described previously ([@R18]). Representative areas from the FFPE breast tissue were placed in a recipient block using 0.6 mm cores for the TFBCS and the NBT sets and using 1 mm cores for the IBC series.

Antibodies, Immunofluorescent Staining and Quantitative Analysis using the AQUA method {#S8}
--------------------------------------------------------------------------------------

These methods are all described in our previous work \[[@R9]\] and in the supplementary methods online.

Statistical Analysis {#S9}
--------------------

TQI design: The goal of this procedure was to identify pairs of markers such that the difference between their AQUA scores is indicative of the time to fixation of the corresponding tissue. To simplify the design we divided the times to fixation in two groups, according to whether the time was longer or shorter than 60 minutes, which was roughly the median time to fixation in our dataset. We divided our dataset in 3 groups, two of which were used for training and one was used as the test set. We used the training set to construct and screen predictions rules for the time to fixation. We then selected the six prediction rules with the largest training performance and computed their test performance. Using the training set, for each pair of markers *j* and *k* computed a screening score based on the differences of AQUA scores for the two markers across all patients as follows: $S_{jk} = \sum\limits_{i = 1}^{N}{\tanh\left\lbrack {\left( {x_{ij} - x_{ik}} \right)\log_{2}\left( {t_{i}/60} \right)} \right\rbrack}$, where *N* is the number of samples (patients) in the training set, *x~ij~* and *x~ik~* are the AQUA scores of markers *j* and *k* marker for sample (patient) *i* and *t~i~* is the time to fixation in minutes for sample (patient) *i*. The difference is weighted by the term log~2~(*t~i~*/60), which was used to favor pairs of markers whose difference had a different sign depending on whether the time to fixation (TTF) was longer or shorter than 60 minutes. The formulation as log~2~(*t~i~*/60) was chosen to reduce contributions to the score from samples with time to fixation around 60 minutes and thus reduced the effects of time measurement precision on defining whether a time to fixation was longer or shorter than 60 minutes. The logarithm was introduced to reflect the notion of exponential decays in markers half-lives, as well as the desired change of sign in the difference of AQUA scores in samples with time to fixation larger than the reference time of 60 minutes. The hyperbolic tangent represents a smooth threshold to limit spurious outliers. For each pair of markers, *j* and *k*, we derived a prediction rule *R~jk~*. The rule *R~jk~* predicts that the time to fixation is larger than 60 minutes when the AQUA score of marker *j* is larger than the AQUA score of marker *k*. For each prediction rule R~jk~ we computed its performance using the Area Under the receiver-operator characteristic Curve (AUC) on the training set. The AUC measured the ability of the difference between the AQUA scores of two chosen markers to correctly classify whether a TTF was longer or shorter than 60 minutes. Finally, we determined the test performance of the six rules with the largest training performance by computing their AUC on the test data. The chosen design addresses the inherent variability of biological samples by comparing two markers at a time. Our procedure favored pairs of markers such that the AQUA score of one increases with time to fixation, while the other decreases. For further validation of the TQI performance linear regressions were computed for log~2~ transformed time to fixation and the TQI components. 95% CIs were calculated using the bootstrapping approach (n=5000). Statistical analyses were performed using the R package ([www.r-project.org](www.r-project.org)*).*

Results {#S10}
=======

Quantification of protein expression according to delayed time to formalin fixation {#S11}
-----------------------------------------------------------------------------------

To construct the TQI, the antibodies described in [Table 1](#T1){ref-type="table"} were all tested on the TFBC series and their expression levels and possible changes as a function of pre-analytical variables were measured. These results have been described previously ([@R16]). Briefly -- housekeeping genes do not lose antigenicity with increasing time to formalin fixation, while proteins of hypoxia and some posttranslational modifications significantly increase in expression. Other biomarkers, such as phospho-tyrosine or phospho-Erk1/2 are more labile and show significant degradation with increasing time to fixation.

The Tissue Quality Index (TQI) as an intrinsic control to assess delay to formalin fixation {#S12}
-------------------------------------------------------------------------------------------

The TQI was constructed using a subset of the TFBC series and its performance measured on a validation subset of the same array. Construction and performance of the TQI are described in [Figure 1](#F1){ref-type="fig"}. The best candidate TQIs consisted of five pair wise combinations of proteins. The AQUA scores of all proteins were log~2~ transformed and subtracted from each other, with phospho-Tyrosine:phospho-HSP27 (pHSP27) performing best, the AUC value being 0.75, followed by Cytokeratin:pHSP27 and pERK1/2:pHSP27 with training set AUC values between 0.6 and 0.7 ([figure 1A](#F1){ref-type="fig"}) and testing set somewhat lower. The predictive value of the TQI regarding delayed time to fixation was then assessed on the complete TFBC series ([Figure 1B and C](#F1){ref-type="fig"}). A negative TQI value means that log~2~ normalized AQUA scores of pHSP27 are higher than the log~2~ normalized AQUA scores of phospho-Tyrosine or Cytokeratin or pERK1/2. This suggests that the tissue may have suffered loss of antigenicity caused through delay in formalin fixation or other less well defined pre-analytic variables. The number of specimens with negative TQI values appears to be associated with prolonged cold ischemic time on the TFBC series.

Validation of the TQI on two independent breast tissue validation cohorts {#S13}
-------------------------------------------------------------------------

We then validated the TQI and its performance on two independent cohorts of breast tissue, the NBT series and the IBC series, both of which consist of breast tissue with recorded cold ischemic time. Due to the lack of lot to lot reproducibility of all tested phospho-Tyrosine antibody cocktails, and/or high levels of heterogeneity of the proteins targeted by this antibody, we were not able to reproduce our original results for phospho-Tyrosine and therefore omitted this epitope from the TQI. The other biomarkers, pHSP27, Cytokeratin and pERK1/2 showed robust reproducibility and were used in the validation of the TQI.

Before assessing the validation cohorts, we tested the TQI on a unique build (different TMA master block) of the TFBC series, which had initially served as the train/test cohort. We were able to show reproducibility of our original result, suggesting that this TQI is independent of biomarker heterogeneity seen for Cytokeratin, pERK1/2 and pHSP27. The performance of the TQI was also validated and measured on this new build of the TFBC series. Linear regressions between increasing time to fixation and the differences of AQUA scores of the TQI markers were computed. Larger differences of the TQI makers correspond with shorter time to fixation measures for a time window of 30 to 120 minutes ([Figure 2A](#F2){ref-type="fig"}).

This proof of principle was followed by validation on the NBT series and the IBC series. Negative TQI values are correlated with increasing delay to formalin fixation on the NBT series, indicating potential for detection of pre-analytic epitopic degradation ([Figure 2B](#F2){ref-type="fig"}). Chi Square analysis of each TQI and the combination of both shows a statistically significant association with time to fixation in this series ([figure 2C](#F2){ref-type="fig"}). The performance of the TQI on build 2 of the TFBC series and the NBT series was also assessed by calculation of the area under the curve (AUC) of a ROC curve and showed values of 0.6 to 0.7 for these marker combinations recapitulating our original result (not shown). The IBC series consists of patient samples which were vacuum sealed and stored at 4º C (UVSC) to prevent degradation. While this is not the current standard of care, we used this cohort since this method represents an alternative approach to diminishing the effects of cold ischemic time. The quantification of pHSP27, Cytokeratin and pERK1/2 and calculation of the TQI revealed mainly positive TQI scores (147 out of 169 readable samples have a positive TQI -- the series consists of 100 patients, represented in 2 fold redundancy on the TMAs) suggesting better preservation of the tissue through vacuum sealing and storage at 4º C ([Figure 2D](#F2){ref-type="fig"}).

TQI value and quantitative ER expression in breast tissue {#S14}
---------------------------------------------------------

Recent publications have shown that there is no loss of ER expression for tissue fixed within one hour of cold ischemic time ([@R16]). However, loss of ER antigenicity has been reported for longer cold ischemic times ([@R6], [@R9]). Here we determine if the TQI can indicate loss of ER reactivity. Specifically, we hypothesize that cases with a negative TQI should have lower ER scores. ER was measured by QIF with the clone SP1 on all 3 breast tissue series. We showed that negative TQI values are significantly correlated with lower ER AQUA scores on the NBT series and the IBC series ([Figure 3 A and B](#F3){ref-type="fig"}), with p-values of 0.03. The correlation of TQI values and ER AQUA scores on build 2 of the TFBC series trends toward significance (p=0.067) but the majority of samples in this series were formalin fixed within 2 hours. The expression levels of the proteins included in this TQI (pHSP27, Cytokeratin and pERK1/2) do not show any correlation with ER expression as tested by Pearson's Correlation Coefficient of each protein separately (data not shown). Thus the association of the TQI and ER AQUA scores appears to be a function of tissue quality and not a coincidental correlation of the TQI proteins and ER expression.

Discussion {#S15}
==========

A clinical mishap in Canada and a series of papers focusing on pre-analytic variables have illustrated the need for a mechanism for tissue quality assessment ([@R2], [@R5], [@R19]). In response to these reports and new ER, PR and HER2 guideline recommendations from the ASCO/CAP panel, efforts have been made to control pre-analytical variables, especially cold ischemic time, to standardize companion diagnostic testing ([@R10], [@R11]). However, these standards cannot always be met and clinicians and researchers are often confronted with the challenge of accurate molecular characterization of tissue samples of unknown quality. Here we describe for the first time the construction of an internally calibrated tool consisting of 3 epitopes and their relative changes to assess the effects of cold ischemic time and the suitability of a given tissue for further immunological assessments.

While substantial efforts in our field have improved standardization and documentation of tissue harvesting and companion diagnostic testing, controlling and minimizing pre-analytical variables on tissue is still problematic and it is not hard to imagine a situation in which a TQI is needed. If for example, if a breast cancer specimen of unknown quality tests negative for ER, one could envision assessment of the TQI to discount false negative results caused through protein degradation. The TQI could also be envisioned to be applied to all specimens received for a clinical trial where tissue is collected from a wide range of sites around the world with less standardized laboratory settings. In this context the TQI could prove that the tissue had the capacity to inform for the companion diagnostic test or it could suggest elimination of that data point in the subsequent biomarker analysis due to poor tissue quality. Finally, the TQI could be used on retrospective studies based on archived tissue collections where information on postsurgical tissue processing was not available. In each case, testing the quality of the tissue could provide better accuracy, reproducibility and applicability for research based on *in situ* biomarker evaluation.

Although the antibodies used for construction of the TQI were validated and the results of the TQI and its relationship to prolonged cold ischemic time and ER expression levels were reproducible on different breast tissue series, our work should be considered as pilot data and a proof of concept, rather than a definitive TQI test. This first study is subject to a number of limitations. Perhaps the most significant is the low sensitivity and specificity for prediction. The performance of the two marker combinations -- Cytokeratin:pHSP27 and pERK1/2:pHSP27 -- as measured by AUC value, ranges from 0.6 to 0.7 showing the assay is accurate only between 2/3 and ¾ of the times. Even though the TQI value is significantly correlated with increasing cold ischemic time, a performance of 0.6 to 0.7 AUC value suggests that several specimens in these breast tissue series are misclassified with respect to their potential loss of antigenicity.

A second major limitation of this TQI test is that it was constructed using only breast cancer tissues. Although it validated on two independent tissue sets, the IBC series were treated with different pre-analytical variables (UVSC conditions) ([@R17]) resulting in better preservation of biomarker expression as compared to the other 2 breast tissue series. In the future, we envision applicability of future TQIs in many other tissue types.

Finally, any TQI will always be limited by the variability in the epitope degradation rate between different epitopes. Here, we focused on ER where we observed a significant association of lower ER expression levels with negative TQI values in two out of the three breast cohorts used for this study. However, the TQI might be better or worse if other epitopes were assessed. It is possible that to be highly accurate in assessment of tissue quality, a unique index may be required for certain classes of proteins or even for individual proteins. For example, phospho-epitopes on tyrosine appear to be highly labile and might require a different TQI than more stable structural proteins like Tubulin or Actin.

The variable rate of degradation of epitopes raises the question of the time window for the TQI. It has been previously shown that the bulk of the degradation of ER does not occur within the first few hours of delay to formalin fixation but rather at a later time window ([@R6], [@R8], [@R9]). This observation may explain why we did not observe a significant loss of ER AQUA scores for patients with a negative TQI on the TFBC series where most of the cases where fixed within 2 hours. In comparison, in the longer NBT and IBC sets, where delay to fixation was stretched to 48 hours or more, the TQI performed better. In the future one can envision different TQIs constructed for different time windows, depending on the specific projected application for the TQI.

In summary, for the first time, we report the construction of a TQI which serves as an intrinsic control of tissue quality. While this work is preliminary and further optimization of this TQI is necessary to improve its performance and applicability to multiple tissue types, it represents a proof of concept for the potential for quantitative quality assessment of tissue specimens. We are hopeful that this approach to quantitative measurement of 3 or 4 biomarkers and their relative changes/relationships to each other can provide a tool to monitor effects of pre-analytical variables on tissue specimens. In the future, we believe we will see more sensitive and specific tools for assessment of quantitative assessment tissue quality.
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:   Area Under the receiver-operator characteristic Curve

AQUA

:   Automated Quantitative Analysis

ASCO

:   American Society of Clinical Oncologists

CAP

:   College of American Pathologists

FFPE

:   formalin fixed, paraffin embedded

IBC

:   Italian Breast Cancer Series

NBT

:   Normal Breast Tissue Series

TFBC

:   Time to Fixation Breast Cancer Series

TMA

:   tissue microarray

TQI

:   Tissue Quality Index

TTF

:   time to fixation

QIF

:   Quantitative Immunofluorescence

UVSC

:   under vacuum sealing and stored at 4º Celsius
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A\) The performance of 6 marker combinations on the testing and validation subgroup of the Time to Fixation Breast Cancer Series as measured by ROC curves and AUC values. The TQI was then calculated on the complete Time to Fixation Breast Cancer Series. Panel B illustrates the TQI values of Cytokeratin:pHSP27 and Panel C pERK1/2:pHSP27 in relationship with increasing cold ischemic time.
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Validation and performance of the TQI on the TFBC, the NBT and IBC series: Panel A: Linear regressions between increasing time to fixation (log2 transformed) and the differences of AQUA scores of the TQI markers as performance measurement on an independent built of the TFBC. Higher values correspond with shorter time to fixation. The dotted line shows the 95% CI of the regression line. Panel B: TQI pairs on each time-point of the NBT series. Panel C: Chi squared analysis of the different TQI components. While each marker combination by itself shows a significant correlation to increasing cold ischemic time, the combination of the separate TQI components facilitates the identification of a larger number of samples, which may have compromised tissue quality. Panel D: The TQI performance on the IBC series where special fixation conditions appears to result in significantly less epitope degradation.
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![Measurement of the TQI performance as a function of ER expression levels quantified by AQUA. Negative TQI values are significantly associated with lower ER AQUA scores on the NBT series and the IBC series (A and B), while the correlation between TQI values and ER expression does not reach significance on build 2 of the TFBC series.](nihms560292f3){#F3}
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Antibodies tested for the TQI

  Symbol                                            Description                                            Antibody                 Supplier
  ------------------------------------------------- ------------------------------------------------------ ------------------------ ---------------------------
                                                                                                           **Clone/Isotype**        
  ***Markers of Cold Ischaemia***                                                                                                   
  ACTB                                              Beta-Actin                                             13E5/IgG                 Cell Signaling Technology
  TUBB                                              Beta-Tubulin                                           pF3/IgG                  Cell Signaling Technology
  GAPDH                                             Glyceraldehyde-3-phosphate dehydrogenase               14C10/IgG                Cell Signaling Technology
  HIST4                                             Histone 4                                              L64C1                    Cell Signaling Technology
  HIST3                                             Histone 3                                              96C10/IgG1, kappa        Cell Signaling Technology
  LMNA/C                                            Lamin A/C                                              polyclonal               Cell Signaling Technology
  LDHA                                              Lactat Dehydrogenase                                   IgG, C4B5                Cell Signaling Technology
  ERalpha                                           Estrogen Receptor alpha                                SP1/IgG                  Thermo Scientific
  CK                                                Cytokeratin                                            AE1/AE3/IgG1             DAKO
  CK                                                Cytokeratin                                            polyclonal               DAKO
  p53                                               Anti-Human p53 protein                                 IgG2b. DO-7              DAKO
  ***Markers of Hypoxia***                                                                                                          
  CCND1                                             Cyclin D1                                              IgG/SP4                  Thermo Fisher Fremont
  Caspase                                           Cleaved Caspase 3 (Asp175)                             polyclonal               Cell Signaling Technology
  HIF1                                              Hypoxia Inducible Factor 1                             polyclonal               Novus Biological
  AKAP13                                            A-kinase anchoring protein13                           IgG2a/ZX-18              Santa Cruz Biotechnology
  CDC42                                                                                                    IgG3/B-8                 Santa Cruz Biotechnology
  CCNB1                                             Cyclin B1                                              GNS-11/IgG2              BD Biosciences
  HIF-2alpha                                        Hypoxia inducible factor - 2alpha                      ep190b/IgG1              abcam
  CA9                                               Carbonic Anhydrase IX                                  polyclonal(aa581--592)   Lifespan Biosciences
  ***Markers of phosphorylated proteins***                                                                                          
  pAKT 473                                          phospho-Akt (ser473)                                   D9E/IgG                  Cell Signaling Technology
  pERK1/2                                           Phospho-p44/43MAPK (Erk1/2) (Thr292/Tyr204)            IgG                      Cell Signaling Technology
  pER                                               Phospho-Estrogen Receptor alpha (Ser118)               16J4/IgG2b               Cell Signaling Technology
  Anti-Phosphotyrosine                              4G10 Anti-Phosphotyrosine                              IgG2b                    Millipore
  Anti-Phosphotyrosine                                                                                     p-Tyr-100                Cell Signaling Technology
  pHSP27 (pS78)                                     phosphorylated Heat Shock Protein 27                   Y175                     Epitomics
  pHer2 (Tyr1248)                                   Phospho-Her2/ErbB2 (Tyr1248)                           PN2A                     Thermo Scientific
  Phospho-Stat3 (Tyr705)                            Phospho-Stat3 (Tyr705)                                 D3A7/IgG                 Cell Signaling Technology
  p-S6 Ribosomal Protein (Ser235/236)               Phospho-S6 Ribosomal Protein (Ser235/236)              D52.2.2E/IgG             Cell Signaling Technology
  Phospho-Jak2 (Tyr1007/1008)                       Phospho-Jak2 (Tyr1007/1008)                            polyclonal               Cell Signaling Technology
  Phospho-Met (Tyr1234/1235)                        Phospho-Met (Tyr1234/1235)                             IgG                      Cell Signaling Technology
  Phospho-Sapk/Jnk                                  Phospho-Sapk/Jnk                                       IgG                      Cell Signaling Technology
  Phospho mTor (Ser2448)                            Phospho mTor (Ser2448)                                 49F9/IgG                 Cell Signaling Technology
  ***Markers of posttranslational modification***                                                                                   
  Sumo1                                             small ubiquitin related modifier 1                     Y299/IgG                 abcam
  Acetylated-Lysine                                 proteins posttranslat. Modified by acetylation         polyclonal, purified     Cell Signaling Technology
  NEDD8                                             neural precursor cell-expr. devel. Downreg. protein9   IgG, 19E3                Cell Signaling Technology
